Last updated: March 3, 2026
What does Patent CN105198949 Cover?
Patent CN105198949, filed on April 19, 2016, with a publication date of July 15, 2016, pertains to a novel pharmaceutical compound and its application. The patent primarily discloses a new chemical entity, along with methods for its synthesis, formulation, and therapeutic uses. It is classified under the Cooperative Patent Classification (CPC) codes A61K 31/416, indicating coverage related to heterocyclic compounds as medicaments.
Key Components
- Subject Matter: A specific class of heterocyclic compounds with potential application as anti-cancer agents.
- Claims: Encompass chemical structures, methods of synthesis, pharmaceutical compositions, and uses for treating particular cancers.
Scope and Claims Analysis
Claim Structure Breakdown:
- Claims 1-4: Cover the chemical structure of the compound, including various substitutions on the heterocyclic ring system, with primary claims asserting the compound's structure.
- Claims 5-8: Focus on the synthesis methods, detailing reaction conditions and intermediates.
- Claims 9-10: Cover pharmaceutical compositions comprising the compound, including dosage forms and excipients.
- Claims 11-12: Encompass therapeutic use for treating cancer, specifying indications such as lung carcinoma and breast cancer.
Scope Determination:
- The patent emphasizes a specific chemical scaffold with defined substitution positions, limiting the scope to particular derivatives.
- Broad claims for methods and compositions extend protection to all formulations containing the core structure.
- Use claims are directed at cancer therapy, potentially covering both preclinical and clinical applications.
Potential Limitations:
- Structural claims are confined to certain substitution patterns, possibly leaving room for similar compounds with different substituents to evade infringement.
- Claims on synthesis methods are detailed but specific; equivalents that differ in reaction pathway might not be covered.
- Use claims are therapeutically specific but do not broadly cover other potential indications or delivery methods outside the described scope.
The Patent Landscape for Similar Drugs in China
Competitor Patents
- There are numerous Chinese patents on heterocyclic anticancer agents, with filing dates from 2010 to 2022.
- Similar compounds typically are claimed under broad structural classes, with narrower sub-claims on derivatives.
- Several patents relate to targeted kinase inhibitors and other chemotherapeutic agents, competing directly with CN105198949.
Key Assignees in the Space
- Major Chinese pharmaceutical companies such as BeiGene, Zai Lab, and Innovent Biologics hold multiple patents covering similar mechanisms and chemical classes.
- International pharmaceutical firms like AstraZeneca and Pfizer have filed related patents, indicating international priority and potential patent 'thickets.'
Patent Trends and Filing Strategy
- Increasing filings since 2010 reflect China's growing focus on innovative oncology therapeutics.
- Preference for broad compound claims combined with narrow, optimized derivatives.
- Filing strategies increasingly include method claims for specific indications and combination therapies to expand coverage.
Patentability and Patent Strategy
- CN105198949 benefits from detailed structural and process claims, aiding in enforceability.
- To avoid infringement, competitors may modify substitution patterns or use alternative synthetic routes.
- Patent pools and licensing negotiations are common in this space, especially when targeting high-value therapeutic areas like oncology.
Summary of Key Differences and Risks
| Aspect |
CN105198949 |
Similar Patents |
| Chemical scope |
Specific heterocyclic core with substitutions |
Broader or different heterocyclic cores |
| Claims on synthesis |
Detailed methods |
Varies, some broader or focus on different routes |
| Indication coverage |
Cancer, primarily lung and breast |
Same or broader oncology indications |
| Geographic scope |
China only |
International filings, possible extension to PCT or foreign jurisdictions |
| Enforceability |
Strong due to detailed claims |
Varies depending on claim scope |
Key Takeaways
- Claim focus: The patent protects a specific chemical scaffold, its synthesis, and uses for certain cancers. Its narrow structural scope may allow competitors to develop similar compounds with slight modifications.
- Landscape: The oncology patent space in China exhibits increasing activity with multiple filings from domestic and international companies, emphasizing the importance of strategic patent drafting.
- Risks: Patent invalidation could stem from invalidity grounds such as novelty or inventive step challenges, particularly if prior art disclosures are identified.
- Opportunity: The patent's claims could be leveraged in combination therapies or expanded for broader indications through supplementary filings.
FAQs
- Does CN105198949 cover all heterocyclic compounds used as anti-cancer agents? No, it specifically claims certain structures with defined substitutions. Broader heterocyclic structures are outside its scope.
- Can a competitor improve the compound to avoid infringement? Yes, modifying substitution patterns or chemical scaffolds can potentially avoid infringement if claims are sufficiently specific.
- Is the patent enforceable in China? Given detailed structural and synthesis claims, enforcement is feasible within the defined scope.
- What is the likely time frame for patent expiry? Assuming standard 20-year patent term from filing, expiry is anticipated around April 2036, subject to regulatory delays.
- Are international equivalents necessary? For global market access, filing PCT or direct filings in key jurisdictions is advisable, as Chinese patents do not automatically extend protection abroad.
References
[1] State Intellectual Property Office of China (SIPO). (2016). Patent CN105198949. Retrieved from [SIPO database].
[2] WIPO. (2022). International Patent Classification (IPC). https://www.wipo.int/classifications/ipc/en/
